Xenpozyme®

Understanding Xenpozyme®

Xenpozyme® is an enzyme replacement therapy used to treat Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann-Pick disease type A and B. This therapy works by replacing the missing or deficient enzyme, acid sphingomyelinase (ASM), in patients with ASMD. By restoring ASM activity, Xenpozyme® helps break down sphingomyelin, thereby reducing harmful buildup in organs and improving lung function, liver and spleen size, and overall symptoms.

How Xenpozyme® Works:

• Restores ASM enzyme activity to break down sphingomyelin
• Reduces organ enlargement, including the liver and spleen
• Improves lung function and other systemic symptoms caused by ASMD

FDA Approval:

• Xenpozyme®: Approved on August 31, 2022

For more information, please visit the Xenpozyme® patient website and speak with your healthcare provider to determine if Xenpozyme® is the right treatment option for you.